The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.

The blood screening market encompasses a range of diagnostic procedures used to test donated blood for infections, diseases, and other health conditions before it is used for transfusions or other medical purposes. This market plays a critical role in ensuring the safety of blood supplies and preventing the transmission of infections such as HIV, hepatitis B and C, syphilis, and other transfusion-transmissible diseases. Driven by increasing demand for safe blood, rising awareness about blood-related disorders, and advancements in screening technologies such as nucleic acid testing and immunoassays, the Blood Screening Market continues to expand. Government initiatives, stringent regulations, and the growing need for early disease detection further contribute to the growth of this essential healthcare sector.

Continue reading for more details:

https://www.fortunebusinessinsights.com/blood-screening-market-102552

Market Segmentation

• By Technology: Includes serological testing, NAT (nucleic acid testing), immunoassays, and rapid tests in the Blood Screening Market.

• By Application: Segmented into donor blood screening, infectious disease detection, oncology markers, and genetic/therapeutic monitoring within the Blood Screening Market.

• By End User: Comprises blood banks, diagnostic laboratories, hospitals, and academic/research institutions in the Blood Screening Market.

• By Test Type: Covers screening for HIV, hepatitis B and C, syphilis, Zika, West Nile virus, and emerging pathogens in the Blood Screening Market.

List Of Key Companies Profiled:

• Bio-Rad Laboratories, Inc.

• Grifols, S.A.

• Hoffmann-La Roche

• Ortho Clinical Diagnostics

• BD

• DiaSorin S.p.A.

• Thermo Fisher Scientific Inc.

• Abbott

• QUOTIENT

• Other Players

Market Growth

• The Blood Screening Market is expanding rapidly due to heightened focus on early disease detection and preventive healthcare.

• Rising incidence of infectious diseases and blood-transmissible infections is driving adoption in the Blood Screening Market.

• Technological innovations in immunoassays, molecular diagnostics, and automation are accelerating growth across the Blood Screening Market.

• Increasing demand for blood safety in transfusion and donation programs supports growth in the Blood Screening Market.

• Stringent regulatory standards and accreditation requirements are pushing laboratories and hospitals to invest in advanced solutions within the Blood Screening Market.

Restraining Factors

• High costs of advanced screening technologies and infrastructure limit accessibility in parts of the Blood Screening Market.

• Regulatory complexity and variable accreditation norms across regions impede standardized adoption in the Blood Screening Market.

• Shortages of skilled laboratory personnel and training challenges constrain growth within the Blood Screening Market.

• Cold‑chain logistics and supply challenges for reagents and consumables may hamper expansion in remote settings of the Blood Screening Market.

• Data management, interoperability issues, and privacy concerns around sensitive health information pose hurdles in the Blood Screening Market

Regional Analysis

• North America: Leads the Blood Screening Market, supported by advanced healthcare infrastructure and rigorous safety regulations.

• Europe: Strong position in the Blood Screening Market, characterized by coordinated public health programs and established blood donation networks.

• Asia‑Pacific: High-growth Blood Screening Market region, due to expanding healthcare access, rising disease burden, and growing screening initiatives.

• Latin America: Emerging potential in the Blood Screening Market, driven by improvements in healthcare delivery and increasing donor screening protocols.

• Middle East & Africa: Gradual expansion of the Blood Screening Market, aided by international collaborations, enhanced awareness, and investment in public health infrastructure.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free)

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com